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Objective: The brachiobasilic arteriovenous ﬁstula (BBAVF) can be formed in one or two stages. This study examined the
failure rates and functional patencies of one-stage vs two-stage brachiobasilic transposition ﬁstulas to compare the two
surgical techniques.
Methods: We retrospectively identiﬁed all the patients who underwent BBAVF access surgery at King’s College Hospital
between January 1, 2009, and December 31, 2011 (3 years). Patients were divided into two groups according to one-
stage or two-stage procedure. All patients were seen in the access clinic 4 to 6 weeks postoperatively, and their ﬁstulas
were scanned (duplex). The surveillance of ﬁstulas consists of duplex scans every 6 months to assess volume ﬂow.
Results: During the study interval, 149 brachiobasilic transpositions (65 one-stage and 84 two-stage) were performed in
141 patients. Patients undergoing the two-stage procedure had a smaller mean preoperative vein diameter (4.0 6 1.1 vs
3.6 6 1.3 mm; P [ .041) and tended to be older (58 6 15 vs 63 6 15 years; P [ .062). Mean overall follow-up was
559 6 333 days. There was no difference in primary failure between the two groups (45% vs 42%; P[ .718). At 1 year,
the two-stage BBAVFs had signiﬁcantly better primary (71% vs 87%; P[ .034), assisted primary (77% vs 95%; P[ .017),
and secondary functional (79% vs 95%; P[ .026) patencies. The same applied to 2-year primary (53% vs 75%; P[ .034),
assisted primary (57% vs 77%; P[ .017), and secondary functional (57% vs 77%; P[ .026) patencies. Multivariate Cox
regression showed that the one-stage procedure was 3.2 times more likely to fail (P [ .028). Men were 2.7 times more
likely to lose their access (P [ .054).
Conclusions: This study describes a large series of BBAVFs and makes an extensive comparison between the one-stage
and two-stage operations. Signiﬁcantly improved overall functional patency is demonstrated for the two-stage
operation. (J Vasc Surg 2013;58:1300-4.)The use of the basilic vein for an autogenous ﬁstula
creation is often considered a complex vascular access
procedure, usually involving a general anesthetic and signif-
icant surgical dissection. However, when other simple
ﬁstula options are exhausted, the basilic vein, lying deep
and protected from damage by venipuncture, makes an
excellent hemodialysis conduit.
The brachiobasilic arteriovenous ﬁstula (BBAVF) was
ﬁrst described by Dagher1 in 1976. Several modiﬁcations
of the initial operation have been developed in the years
since then.2,3However, the basic principle is to superﬁcialize
the basilic vein and make it amenable to needle puncture.
The BBAVF can be formed in one stage or two stages.
To date, limited and conﬂicting data exist regarding
primary failure and the patency rates of one-stage and
two-stage procedures.4-12 Each procedure has advantages
and disadvantages. The one-stage procedure offers the
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0and possible shorter duration with a central venous cath-
eter. The advantage of a two-stage procedure is the ease
of mobilization of a larger “arterialized” vein, rendering
it less susceptible to torque and devascularization during
mobilization.13 If surgical revision for postanastomotic
stenosis is required, this is easily performed at the second
stage. In case of early failure, the patient is spared a general
anesthetic and signiﬁcant surgical dissection. However, the
two-stage procedure necessitates two operations, which
may affect operating theater capacity and delay acquisition
of permanent access.
In this study, we examined primary failure rates and
the primary, primary assisted, and secondary functional
patencies of one-stage vs two-stage brachiobasilic transpo-
sition ﬁstulas to compare the two surgical techniques. The
hypothesis is that two-stage BBAVFs provide longer
patency. In addition, we examined the effect of patient
variables on the ﬁnal outcome.
METHODS
Design and patients. We retrospectively identiﬁed all
patients who underwent BBAVF at King’s College
Hospital between January 1, 2009, and December 31,
2011 (3 years). Patients who underwent creation of a
brachiobasilic transposition ﬁstula were divided into groups
according to one-stage or two-stage procedures. During
this 3-year period, 149 BBAVFs were formed in
141 patients. The patients were consecutive, and two
experienced surgeons performed the operations. One of
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whereas the other usually performs the two-stage one. In
patients with small-sized veins, both surgeons would
mostly perform the procedure in two stages. Minimum
vein threshold for AVF is 2 mm, as determined by preop-
erative vein mapping, which was performed without the
use of tourniquet on all patients.
All patients were seen in the access clinic 4 to 6 weeks
postoperatively, and their AVFs underwent duplex scan-
ning to assess maturation. Once in use, the ﬁstulas entered
the surveillance program of 6-month duplex scanning of
volume ﬂow. Prolonged bleeding, raised static venous pres-
sure (>170 mm Hg), inability to achieve blood pump
speed of 300 mL/min, urea reduction ratio <65%, and
dialyzer clearance of urea (K) dialysis time (t)/volume of
distribution of urea (V) <1.2 prompted referral for
ﬁstuloplasty. Stenotic areas on duplex imaging were consid-
ered for ﬁstuloplasty if they affected the quality of
hemodialysis.
Deﬁnition of variables. Primary patency (interven-
tion-free access survival) was deﬁned as the interval from
time of access placement to any intervention designed
to maintain or re-establish patency.14 Assisted primary
patency (thrombosis-free access survival) was deﬁned as the
interval from time of access placement to access throm-
bosis.14 Secondary patency (access survival until abandon-
ment) was deﬁned as the interval from time of access
placement to access abandonment. A functional AVF is an
access that is able to deliver a ﬂow rate of 350 to 400 mL/
min without recirculation for the total duration of dialysis.
A nonfunctional AVF is an access that is not being success-
fully used for hemodialysis, regardless of whether it is
patent.14
Primary failure was deﬁned as an AVF that was never
used for dialysis. This deﬁnition includes (1) inadequate
maturation, (2) early thrombosis, (3) failure of ﬁrst cannu-
lation, and (4) other complications, such as ischemia or
infection, which made it unusable.
This study refers to primary functional, assisted primary
functional, and secondary functional patency. Therefore
AVFs that were not used for dialysis were not included in
the survival models.
All complications were extracted from the electronic
patient records. Early complications are deﬁned as occur-
ring #30 days from the operation date.
Description of surgical technique. The one-stage
operation is performed under general anesthesia. A 5-cm
incision at the antecubital fossa identiﬁes the basilic vein.
Brachial vein ﬁstulas were not included in this series.
Intraoperative ultrasound imaging was not used. The
incision is extended proximally, and the underlying deep
fascia is opened. The basilic vein is mobilized up to its
junction with the brachial vein. The median cutaneous
nerve of the forearm is carefully dissected and preserved.
After side branches are ligated, the basilic vein is tunnelled
subcutaneously, with a Roberts’ forceps maintaining its
axial orientation. An end-to-side arteriovenous anastomosis
to the brachial artery is performed.The ﬁrst stage of the two-stage operation is performed
under local anesthesia by formation of the arteriovenous
anastomosis with minimal disturbance of the basilic vein.
After 4 to 6 weeks, a ﬂow assessment of the AVF by duplex
scanning is made to determine if revision of the anasto-
mosis is necessary at the second stage. The second stage
is performed under general anesthesia. The entire length
of the basilic vein is mobilized, a “subcutaneous ﬂap” is
created, and the vein is positioned anterolaterally. Usually,
a further 4 weeks is required before the AVF can be used.
Statistical analysis. Analyses were conducted using
SPSS 20.0 software (SPSS Inc, Chicago, Ill). Descriptive
statistics were calculated for all variables. Results are shown
as means 6 standard deviation, unless otherwise described.
Categoric variables were compared using Pearson c2 and
Fisher exact tests. The Kolmogorov-Smirnov test was
used to test continuous variables for normal distribution.
Normally distributed data were compared with the t-test
and are expressed as mean 6 standard deviation; otherwise,
the Mann-Whitney test was used and they are expressed as
median and interquartile range. Primary, assisted primary,
and secondary functional patencies were estimated with the
use of the Kaplan-Meier method and were compared with
the log-rank test.
Multivariate Cox proportional hazard models were used
to assess the independent effects of one-stage or two-stage
procedure and other factors on patency and failure rates,
including age >65 years, sex, ethnic origin (white, black,
other), diabetes, body mass index (BMI) >30 kg/m2, and
size of vein <3 mm on preoperative vein mapping. The
selection of the factors was based on previously published
studies. Data from patients who had patent ﬁstulas at the
last follow-up (August 31, 2012) were censored on that
date. Patient deaths unrelated to ﬁstula failure, patients
who had successful kidney transplantation, or those who
were transferred to other dialysis units were censored.
All reported P values are two-sided, and a P value
of <.05 was considered statistically signiﬁcant.RESULTS
From January 1, 2009, to December 31, 2011, 149
brachiobasilic transpositions (65 one-stage and 84 two-
stage) were performed in 141 patients (1.06 operations/
patient). The left arm was used in 99 and the right in
50. Mean follow up was 559 6 33 days (range, 1-1261
days). Median interval between the ﬁrst and second opera-
tion for the two-stage BBAVFs was 90 days (interquartile
range, 68-129 days).
Patients undergoing the two-stage procedure had
a smaller mean preoperative vein diameter (4.0 6 1.1 vs
3.6 6 1.3 mm; P ¼ .041). There was also a trend to use
the two-stage procedure on older patients (58 6 15 vs
63 6 15 years; P ¼ .062; Table I).
The BBAVF was the ﬁrst access in 64 patients (43%),
second in 50 (34%), third in 23 (15%), fourth in six (4%),
ﬁfth in three (2%), and sixth in two (1%). The number of
previous ﬁstulas is not mentioned in two patients (1%).
Fig 1. Kaplan-Meier curve depicts primary functional patency
for one-stage and two-stage brachiobasilic arteriovenous ﬁstulas
(BBAVFs). P ¼ .045.
Table II. Primary failure
One-stage (n ¼ 65) Two-stage (n ¼ 84) P
45% 42% .718
Table I. Patient demographics
Variables
One-stage
(n ¼ 65)
Two-stage
(n ¼ 84) P
Age, mean 6 SD, years 58 6 15 63 6 15 .062
Female sex, % 49 52 .703
Diabetes, % 38 39 .825
Hypertension, % 81 80 .821
BMI, mean 6 SD, kg/m2 29 6 6 27 6 7 .221
Black race, % 45 46 .958
Vein size, mean 6 SD, mm 4.0 6 1.1 3.6 6 1.3 .041
BMI, Body mass index; SD, standard deviation.
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dialysis (66% one-stage vs 60% two-stage; P ¼ .407), and
56 (38%) were not used, of which 19 (34%) failed before
needling, two patients (4%) received a renal transplant,
seven (13%) died, and 28 (50%) BBAVFs remain patent
in predialysis patients (equally distributed between the
two groups).
Primary failure was similar between the two groups
(45% vs 42%; P ¼ .718; Table II). Intervention before ﬁrst
dialysis was similar in the two groups (21% vs 11%; P ¼
.201). Most preemptive interventions were endovascular,
whereas open surgery was reserved for two one-stage
patients. The mean ﬂows at 6 weeks postoperatively were
1256 6 471 mL/min for the one-stage group and
1167 6 439 mL/min for the two-stage group (P ¼ .313).
Primary functional patency, assisted primary functional
patency, and secondary functional patency for both groups
are depicted in Kaplan-Meier graphs seen in Figs 1, 2, and
3, respectively. In the one-stage vs two-stage groups, the
mean primary functional patency was 753 6 88 days and
853 6 59 days (P ¼ .045), mean assisted primary
functional patency was 795 6 79 and 987 6 54 days
(P ¼ .026), and mean secondary functional patency was
803 6 77 and 992 6 52 days (P ¼ .027), respectively.
At 1 and 2 years, the primary, assisted primary, and
secondary functional patency rates were signiﬁcantly better
for the two-stage BBAVFs (Table III).
Risk factors associated with the BBAVF outcome, such
as age >65 years, sex, diabetes, BMI >30 kg/m2, ethnic
origin, and size of the vein (<3 mm) preoperatively were
analyzed in a multivariate Cox proportional hazard model
(Table IV). The overall model was statistically signiﬁcant
(P ¼ .040) and showed that the one-stage procedure was
3.2 times more likely to fail (P ¼ .028) and that men
were 2.7 times more likely to lose their access (P ¼ .054).
There were 27 deaths during the 3-year study period:
10 one-stage patients and 17 two-stage patients (c2
P ¼ .446)Early complications (<30 days) occurred in six patients
(9%). Five patients (two thrombosis, two hematoma, one
steal; 16%) belonged to the one-stage group and one
(hematoma, 2%) was in the two-stage group (Fisher exact
test, P ¼ .078). One early death occurred in the one-
stage stage group, not related to the AVF.
Overall, there was no statistical signiﬁcance comparing
the total complication rate between the two groups (c2,
P ¼ .715). Table V reports the complications encountered
with the respective probability scores.
DISCUSSION
This is the largest single-center study to compare the
functional patencies of one-stage vs two-stage brachioba-
silic transposition ﬁstula. Several previous studies4-12 have
compared the two operations. However, which technique
is superior in long-term patency and complications remains
unclear.
This study adds signiﬁcant data on the functional
patencies, complications, and risk factors associated with
one-stage and two-stage BBAVFs. The primary functional
patency of BBAVFs in this study at 1 year is comparable
to reports published within the last 10 years.12,15-19 Our
data suggest that at 1 year, the two-stage BBAVFs have
signiﬁcantly better primary (71% vs 87%; P ¼ .034), assis-
ted primary (77% vs 95%; P ¼ .017), and secondary (79%
vs 95%; P ¼ .026) functional patencies. A similar trend is
seen for 2-year primary (53% vs 75%; P ¼ .034), assisted
primary (57% vs 77%; P ¼ .017), and secondary functional
(57% vs 77%; P ¼ .026) patencies. These data are in accord
with work by El Mallah,4 who randomized 40 patients to
Fig 3. Kaplan-Meier curve depicts secondary functional patency
for one-stage and two-stage brachiobasilic arteriovenous
ﬁstulas (BBAVFs). The dashed line indicates standard error >10%.
P ¼ .027.
Table III. Patency rates at 1 and 2 years
Interval
Functional
patency
One-stage,
%
Two-stage,
% P
1 year Primary 71 87 .034
Assisted 77 95 .017
Secondary 79 95 .026
2 years Primary 53 75 .034
Assisted 57 77 .017
Secondary 57 77 .026
Fig 2. Kaplan-Meier curve depicts assisted primary functional
patency for one-stage and two-stage brachiobasilic arteriovenous
ﬁstulas (BBAVFs). The dashed line indicates standard error >10%.
P ¼ .026.
Table IV. Multivariate Cox proportional hazard model
Variable Signiﬁcance b (95% CI)
Male sex .054 2.672 (0.985-7.250)
Race
White .540
Black .268 1.820 (0.631-5.247)
Other .806 1.228 (0.238-6.349)
Diabetic .342 1.604 (0.606-4.247)
BMI >30 kg/m2 .139 2.245 (0.770-6.548)
One-stage operation .028 3.180 (1.133-8.927)
Age >65 years .748 1.170 (0.448-3.061)
Vein <3 mm .100 2.343 (0.848-6.470)
BMI, Body mass index; CI, conﬁdence interval.
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rates 50% and 80%, respectively, at a median follow-up of
15 months, indicating a beneﬁt for the two-stage proce-
dure. However, the retrospective study of 70 patients (30
transposed/20 elevated in one-stage and 20 elevated in
two-stages) by Hossny5 showed no signiﬁcant difference
in secondary patency rates at 12 and 24 months between
one-stage and two-stage procedures, at 90% and 84.2% vs
70% and 68.4%, respectively.
Several studies have shown older age is a signiﬁcant fac-
tor in access failure, as well as obesity.15,20,21 Our study did
not show that BMI >30 kg/m2 (P ¼ .139) or older age
(P ¼ .748) had a clear link with access failure. In addition,
our study did not show that diabetic individuals have a worse
ﬁstula outcome, as seen in another study.20 Why men would
be at a higher risk for losing their access is unclear.
The reported complication rate for BBAVF remains
high, between 43% and 71%.5,9,22-24 The 53.7% overall
complication rate in this study is in agreement with such
ﬁndings. Hossny5 showed the complication rate was signif-
icantly higher in the two-stage elevation group compared
with the one-stage transposition group (71.4% vs 28.6%;
P > .001). Kakkos et al,24 however, found the complica-
tion rate was signiﬁcantly higher in the one-stage operation
(43% vs 11%; P < .001). Our study did not show any signif-
icant difference in the complication rates between the two
procedures (P ¼ .715). However, there was a trend toward
more thrombosis in the one-stage operation (4% vs 1%;P ¼ .079) and for more stenosis in the two-stage group
(9% vs 20%; P ¼ .06). Why the two-stage procedure would
present with a higher stenosis rate is unclear, although
Table V. Complications
Variable
One-stage
(n ¼ 65), %
Two-stage
(n ¼ 84), % P
Overall 24 30 .715
Infection 3 2 .297
Hematoma 3 3 .504
Thrombosis 4 1 .079
Steal syndrome 2 3 .1
Venous hypertension 2 1 .318
Stenosis 9 20 .06
JOURNAL OF VASCULAR SURGERY
1304 Vrakas et al November 2013a possible explanation could relate to the smaller vein diam-
eter (4.0 6 1.1 vs 3.6 6 1.3 mm; P ¼ .041).
This study has several limitations. It is a retrospective,
nonrandomized study, therefore allowing for selection
bias. Personal preference of the two operating surgeons
affected the type of the operation, and patients with smaller
veins would mostly be allocated to the two-stage group.
Another limitation is that our survival analysis is based
only on functional BBAVFs (43 one-stage and 50 two-
stage cases).
CONCLUSIONS
This study demonstrates signiﬁcantly improved pri-
mary, assisted primary and secondary functional patency
for the two-stage operation, with a similar complication
rate to the one-stage procedure. The superior functional
patency of the two-stage procedure noted in this study
suggests that the two-stage approach should be the opera-
tion of choice for BBAVFs. However, our results should be
conﬁrmed by a prospective, randomized multicenter trial.
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